Barclays analyst Steve Valiquette raised the firm’s price target on Amedisys (AMED) to $101 from $88 and keeps an Equal Weight rating on the shares. The company now deems UnitedHealth’s previously unsolicited $101 per share cash offer to be a “superior proposal” and terminated its prior Option Care Health (OPCH) merger agreement, the analyst tells investors in a research note. The analyst believes antitrust remains the primary risk to closure given UnitedHealth’s recent LHC Group acquisition.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AMED:
- UNH Gains Slightly after Announcing New Merger Deal
- Option Care Health confirms termination of merger agreement with Amedisys
- Amedisys to combine with Optum in all-cash deal at $101 per share
- Amedisys and Optum to Combine, Advancing Value-Based Care for Patients
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations